dexamethasone

Steroid and NSAID combination prevents macular oedema after cataractsA combination of a topical corticosteroid and a nonsteroidal anti-inflammatory drug (NSAID) is more effective than either one alone in reducing the risk of cystoid macular oedema (CME) after cataract surgery in nondiabetic patients, researchers say.
New technologies on horizon to redefine drug deliveryGlaucoma has an adherence problem. Drugs that are highly efficacious are far less than optimally effective because patients fail to take eye drops properly or don’t take them all. Novel drug-delivery technologies could improve adherence and outcomes.
NICE recommends dexamethasone adalimumab for uveitisThe UK’s National Institute for Health and Care Excellence (NICE) has given preliminary approval to dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) and adalimumab (Humira, AbbVie) for sight-threatening non-infectious posterior uveitis.
Vitrectomy beats scleral buckling in rhegmatogenous retinal detachment studyEyes operated on with pars plana vitrectomy needed fewer reoperations over 180 days than eyes subjected to scleral buckling (SB) in a retrospective comparison of patients with rhegmatogenous retinal detachment (RRD).
Large variety of multiple myeloma treatment options presents challengesThere now exist numerous treatment options for multiple myeloma but how best to sequence them is still under study
Deciphering bacterial meningitisThe introduction of conjugated vaccines has decreased the incidence of bacterial meningitis in children, amounting to one of the biggest public health successes in the practicing pediatrician’s career.
What punctal plug delivery of dexamethasone means for allergic conjunctivitisTreatment of chronic allergic conjunctivitis with a sustained-release dexamethasone resulted in better clinical results because of the sustained and controlled delivery.
Expert reviews myeloma combo treatmentsMyeloma combination treatments get the once-over by leading cancer expert.
FDA approves first immunostimulatory antibody for multiple myelomaAn oncology expert at ASH will present extended follow-up and overall survival data from ELOQUENT-2, the study on which Empliciti is approved.
Top 5 things to know about new myeloma drugIn FDA’s latest approval of a new medication to treat multiple myeloma, the agency approved Ninlaro capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy